India’s pharmaceutical industry has transformed into a global powerhouse, earning the country the reputation of “pharmacy of the world.” It stands as the third-largest producer of pharmaceuticals by volume and 14th by value worldwide 1. This sector has evolved over decades from heavy import dependence post-independence to a position where it now meets 85% of domestic medicine demand and serves markets across the globe. In doing so, it has become a key pillar supporting both India’s economic growth and its social development through healthcare improvements.

Driving Economic Growth and Innovation

The pharmaceutical sector is a major engine of India’s economy. Valued at around US$55 billion as of 2025, it contributes roughly 1.7% to India’s GDP and is on track to reach US$120–130 billion by 2030 2. It is among the top five manufacturing industries in India, supporting approximately 2.7 million jobs directly or indirectly and generating a trade surplus of about US$19 billion annually 2. The industry is also a significant earner of foreign exchange for India, with pharmaceutical exports exceeding US$30 billion in FY2024–25, accounting for about 6% of India’s total merchandise exports by value 3. Such robust performance underscores the sector’s role in driving industrial growth, attracting foreign investment, and fostering innovation in drug development and manufacturing.

India’s pharma companies have achieved a strong global presence, exporting to more than 200 countries. India hosts over 10,000 manufacturing facilities and 3,000 pharma companies, including the largest number of US-FDA compliant plants outside the United States 1. This manufacturing strength, combined with a skilled scientific workforce, has positioned Indian firms to compete internationally and produce medicines at scale. The government has further bolstered the industry with supportive policies. Notably, the Production-Linked Incentive (PLI) scheme for pharmaceuticals was introduced to encourage domestic production of key drug ingredients and boost manufacturing capacity. This initiative has already led to 50+ new pharma plants being established and expanded output in critical drug segments, strengthening supply chains and reducing import dependence 4. Continued investment in research & development, infrastructure, and favorable regulations are set to keep India’s pharma sector on an upward trajectory, with ambitions to become the world’s largest supplier by volume and a top-5 exporter by value in the coming decades.

Advancing Public Health and Social Development

Beyond its economic contributions, India’s pharmaceutical industry plays a vital social role by improving health outcomes and access to medicine both domestically and globally. The industry’s growth has contributed immensely to increasing life expectancy and providing better treatments for numerous diseases by ensuring a reliable supply of affordable drugs 5. Indian pharmaceutical companies are renowned for producing high-quality generics at a fraction of the cost of branded drugs, making lifesaving therapies more accessible for low-income populations. For example, in 2001 an Indian firm revolutionized HIV/AIDS treatment by offering triple therapy for under $1 per day, compared to the prevailing cost of $12,000 per year in many countries – a breakthrough that enabled millions of patients in Africa and other developing regions to afford treatment 5. This landmark move demonstrated how Indian pharma has been pivotal in bringing down the cost of critical medications globally, directly impacting public health in positive ways.

India is also a leading supplier of vaccines and other essential medicines worldwide, underpinning global health programs. It currently provides approximately 20% of generic drugs globally by volume and fulfills about 60% of the world’s vaccine demand 3. Notably, Indian manufacturers supply over 80% of the antiretroviral drugs used in the global fight against HIV/AIDS, a contribution that has been fundamental in controlling the disease’s spread and mortality 6. The country’s capacity to produce high-quality, low-cost vaccines was highlighted during the COVID-19 pandemic, when India supplied vaccines and critical medicines to dozens of nations. These efforts have solidified India’s role as a dependable partner in global healthcare. By ensuring affordable access to treatments for diseases like HIV, tuberculosis, malaria, and many others, the Indian pharma industry has had a profound impact on social development outcomes, from reducing child mortality to improving overall quality of life.

Conclusion

India’s pharmaceutical industry exemplifies how a strong industrial base can serve as a pillar for both economic prosperity and social progress. It generates millions of jobs and substantial export earnings while also saving millions of lives through the supply of affordable, quality medicines. As the industry continues to innovate and expand – supported by government initiatives and its own entrepreneurial drive – it is poised to maintain its dual role in powering India’s economy and advancing global health. In essence, the growth of India’s pharma sector is not just an economic success story; it is a beacon of how industrial development can align with and reinforce broader social development goals, firmly establishing it as a pillar of both India’s economic strength and its commitment to improving lives worldwide.

Sources

1. India Brand Equity Foundation (IBEF) – Pharmaceuticals Industry in India (October 2025). [Link] – India ranks 3rd worldwide in pharmaceutical production by volume and 14th by value.
2. India Brand Equity Foundation (IBEF) – Pharmaceuticals Industry in India (October 2025). [Link] – Industry valued at ~US$55 billion (2025) with ~1.72% GDP contribution; projected US$120–130 billion by 2030; supports ~2.7 million jobs and maintains ~US$19 billion trade surplus.
3. India Brand Equity Foundation (IBEF) – Pharmaceuticals Industry in India (October 2025). [Link] – India supplies ~20% of global generic drugs and ~60% of global vaccines by volume; exports over US$30 billion in FY25.
4. Devdiscourse News – “India's Pharmaceutical Industry Emerges as Key Economic Pillar” (Sept 27, 2024). [Link] – Reference to the success of India’s Production-Linked Incentive (PLI) scheme leading to 50+ new pharma manufacturing plants and increased exports.
5. Indian Pharmaceutical Alliance – “Pharma Industry: A Pillar of India’s Growth” via Times of India (August 15, 2022). [Link] – Indian pharma’s role in increasing life expectancy and the 2001 HIV triple-therapy example (Cipla’s <$1/day treatment vs $12,000/year internationally).*
6. India Brand Equity Foundation (IBEF) – Pharmaceuticals Industry in India (October 2025). [Link] – Over 80% of the global supply of antiretroviral (AIDS) drugs comes from India, reinforcing its moniker “pharmacy of the world.”